HIV News and Research

RSS

Cryptosporidium parvum parasite could help to develope new therapies for the disease

Cryptosporidium parvum, an insidious, one-celled, waterborne parasite that lodges in the intestines of infected people and animals and for which there is currently no effective treatment, is missing key structures normally found in similar parasites, say researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The results of their genome sequencing project, could help scientists home in on new drug targets that may lead to therapies for the disease.

26 Mar 2004

Partnership to improve TB vaccine, Bacillus Calmette-Guérin (BCG)

Crucell N.V.and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, announced today a new collaboration on the pre-clinical and clinical development of candidate tuberculosis (TB) vaccines. Aeras has agreed to provide Crucell up to USD$2.9 million contingent upon meeting certain development milestones, for development of TB vaccine candidates.

25 Mar 2004

£5m for HIV/AIDS trial involving HIV patients in London, Moscow, South Africa and Australia

A joint Oxford University/Imperial College research programme into HIV/AIDS has received £5 million support from the Wellcome Trust to carry out a drug trial involving HIV patients in London, Moscow, South Africa and Australia.

24 Mar 2004

WHO meets in New Delhi on challenge of treating an additional one million patients a year

The number of tuberculosis patients diagnosed and treated under DOTS, the internationally recommended strategy for TB control, is now rising much faster than at any time since DOTS expansion began in 1995, according to a new report by the World Health Organization (WHO). Indeed, the past two years have witnessed accelerated growth in the implementation of DOTS programmes worldwide.

24 Mar 2004

New Cell Sorter Helps Understand Deadly Diseases

Researchers at NC State’s College of Veterinary Medicine have a new state-of-the-art tool, a high-speed cell sorter, that should quicken the pace of their research. The machine sorts or collates cells into groups, allowing scientists to look only at the cells they are working on.

23 Mar 2004

EU gives 32 million Euro for vaccines to stop tuberculosis

The European Commission today launched the largest-ever collaborative tuberculosis (TB) initiative for World TB-day, March 24. Fifty-two research teams from academia and industry from 15 European and African countries are joining forces with the European Commission to help eradicate TB. Globally, TB kills 2 million people a year, with one-third of the world's population currently infected with the bacillus, Mycobacterium tuberculosis (Mtb). While most cases and deaths occur in developing countries, resistant Mtb strains are mainly found among the poorest people in developed countries, as incomplete treatment increases drug resistance. The European Union is confronting the re-emerging threat of TB by investing €32 million in two overlapping research projects. This cash will be used in an accelerated effort to develop new, effective vaccines to fight TB.

23 Mar 2004

Research provides better understanding of lipodystrophies disorders

More than a decade of work conducted by UT Southwestern Medical Center at Dallas researchers has led to a better understanding of the underlying causes of lipodystrophies - disorders characterized by the selective loss of fat tissues, resulting in metabolic complications, such as severe diabetes and high blood cholesterol levels.

22 Mar 2004